Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (ZTEK) generates news across several advanced technology domains, reflecting its role as an intellectual property development and commercialization company. Its disclosures highlight activity in graphene-based coatings, critical mineral development, aptamer-based healthcare technologies and fire-retardant materials, giving investors and observers multiple streams of company-specific updates.
A major news theme is Zentek’s work through its wholly owned subsidiary Albany Graphite Corp. on the Albany Graphite Project in Ontario. Recent releases describe ultra-high purity Albany graphite reaching five-nines carbon purity with an Equivalent Boron Concentration below thresholds generally referenced for nuclear applications, as well as additional nuclear suitability testing and independent verification using near-net-shaped graphite bricks. Separate announcements cover lithium-ion battery suitability testing, where spheroidized Albany graphite has shown near-theoretical anode performance under industry-standard conditions.
Another recurring topic is Zentek’s ZenGUARD™ platform for surgical masks and HVAC air filters, including corporate updates on testing under the Government of Canada’s Innovative Solutions Canada program and efforts to advance ZenGUARD™ Enhanced Air Filters in Canada and international markets. News items also address the company’s development of a Graphite Gel-Based Fire-Retardant product and an exclusive licensing arrangement with Altek Advanced Materials Inc. for commercialization in the United States.
Healthcare-focused news includes progress on multivalent aptamer countermeasures against influenza through Triera Biosciences and McMaster University, supported by a federal testing contract. Corporate governance and capital markets developments, such as CEO transitions, board appointments, annual meeting voting results and tax reassessment matters, are reported through regular press releases and associated Form 6-K filings. Readers following ZTEK news can expect updates on technology milestones, regulatory and testing programs, strategic partnerships and key corporate decisions.
Zentek Ltd. (NASDAQ:ZTEK) has been selected to present its ZenGUARD™ technology at the 12th Annual Global Summit on Regulatory Science in October 2022. The summit focuses on nanotechnology advancements in medical products, and Zentek will showcase its patent-pending antimicrobial coating, proven to have 99% efficacy against various pathogens. Notable speakers from global regulatory bodies, including the FDA and Health Canada, will also participate. Additionally, the company has granted options for 150,000 common shares at $1.93 to certain officers and employees.
Zentek Ltd. (Nasdaq: ZTEK) announced the results from its annual and special meeting held on September 29, 2022. Shareholders approved all resolutions, including the election of the board of directors, with high approval rates: Francis Dube (95.689%), Greg Fenton (98.98%), and Eric Wallman (99.530%). Other approved items include appointing BDO Canada LLP as auditors (98.871%) and adopting a long-term incentive plan (91.766%). Dr. Francis Dube expressed satisfaction with the strong support from shareholders as the company focuses on advancing nanotechnologies.
Zentek Ltd. (NASDAQ:ZTEK) announced that its Canadian patent application for its ZenGUARD™ technology, utilized in personal protective equipment (PPE) and HVAC systems, has been allowed by the Canadian Intellectual Property Office. All 54 claims in the application were granted, marking a significant milestone in Zentek's strategy for global patent protection. CEO Greg Fenton emphasized the importance of this achievement in validating the company's IP development model. ZenGUARD™ has demonstrated 99% antimicrobial activity, including against COVID-19, enhancing its commercial potential.
Zentek Ltd. (NASDAQ: ZTEK) announced that CEO Greg Fenton will present at the Sidoti Small-Cap Virtual Investor Conference on September 22, 2022, at 12:15 PM ET. This annual conference connects small-cap companies with institutional investors. Fenton highlighted the company's strong IP pipeline and opportunities, particularly with ZenGUARD™, which shows 99% antimicrobial activity. Investors can register for the event at Sidoti's website.
Zentek Ltd. (Nasdaq:ZTEK, TSX-V:ZEN) has announced successful tests of its patent-pending Icephobic Coatings at the NRC and AMIL. Results indicate the coatings have a low adhesion ice removal capability, with shear stress remaining below 100 kPa, and effective performance in preventing ice accretion on drones and wind turbines. Notable findings include 1,000 hours of UV exposure showing slight adhesion increase and promising results in sand and rain erosion tests. Zentek aims to address significant ice accretion challenges with this technology, supported by a full patent application filed in August 2022.
Zentek Ltd. (NASDAQ:ZTEK) announced the successful completion of Phase 1 testing for its ZenGUARD™-coated HVAC filters under the Innovation Solutions Canada contract. The tests confirmed a 99% reduction in airborne pathogens without airflow reduction or significant shedding of the coating. CEO Greg Fenton emphasized the technology's potential for improving indoor air quality while maintaining energy efficiency. The company is now advancing to Phase 2 testing in a modular classroom setting to further validate its findings.
Zentek Ltd. (Nasdaq:ZTEK) has announced its 2022 Annual General and Special Meeting to take place on September 29th at 4:00 PM at the Delta Hotel, Guelph, Ontario. Attendance requires registration via email, and the event will also be live-streamed. Shareholders will vote on key items including the appointment of auditors, election of directors, and adoption of a long-term incentive plan. The management information circular will be mailed to shareholders shortly. Zentek focuses on innovative healthcare solutions, particularly antimicrobial coatings and rapid pathogen detection technology.
Zentek Ltd. (NASDAQ: ZTEK) has announced a Manufacturing and Supply Agreement with Viva Healthcare Packaging (Canada) Ltd. to produce surgical masks enhanced with Zentek's proprietary ZenGUARD™ antimicrobial coating. VMedCare, a leader in surgical mask manufacturing, will utilize Zentek's materials to create a fully Made in Canada source of these enhanced masks. This partnership aims to boost sales and meet growing demand, especially as Zentek opens its production facility in Guelph, Ontario.
Zentek Ltd. (Nasdaq:ZTEK, TSX-V:ZEN) has filed a provisional patent for its ZenGUARD™ technology as an anti-inflammatory agent for various dermatological conditions. CEO Greg Fenton emphasized their commitment to patenting and commercialization of ZenGUARD™, which is already authorized by Health Canada as an antimicrobial for surgical masks and PPE. Current research aims to explore its potential for treating conditions like acne, psoriasis, and eczema. The company is collaborating with Vimta Labs for pre-clinical data needed for FDA drug submission.
Zentek Ltd. (NASDAQ:ZTEK) announced the appointment of Ilse Treurnicht to its Board of Directors. Treurnicht, who holds a DPhil in chemistry from Oxford, is the Managing Partner of TwinRiver Capital and has significant Board-level experience, including her role as CEO of the MaRS Discovery District. She has been awarded 250,000 options at $2.44, with a vesting schedule over five years. Zentek focuses on innovative healthcare solutions, including its ZenGUARD antimicrobial coating and exclusive rights to a rapid pathogen detection technology.
FAQ
What is the current stock price of Zentek (ZTEK)?
What is the market cap of Zentek (ZTEK)?
